We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ACMG Releases Policy Statement on Genomic Sequencing
News

ACMG Releases Policy Statement on Genomic Sequencing

ACMG Releases Policy Statement on Genomic Sequencing
News

ACMG Releases Policy Statement on Genomic Sequencing

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ACMG Releases Policy Statement on Genomic Sequencing"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

These new guidelines should help guide clinicians as they use such testing and address:

The categories of patients and types of clinical situations for which such testing will likely be the most helpful

What patients need to know about genomic sequencing before it is performed

Principles that guide the use of information from genomic sequencing to improve patient care and medical decision-making

ACMG President Wayne Grody, M.D., Ph.D., FACMG said upon the Statement's release, "The transition from traditional targeted gene testing to genome-wide analysis constitutes a genuine sea change in medicine, offering vastly enhanced diagnostic power along with unprecedented challenges in test interpretation and reporting. This policy represents the first professional guidance for appropriate integration of this new technology into clinical practice."

"Genomic sequencing is now transitioning from the research laboratory into the clinic and will have a transformative effect on healthcare," said Bruce R. Korf, M.D., Ph.D., FACMG, one of the authors of the new Policy Statement and past-president of the ACMG. "This statement by the American College of Medical Genetics and Genomics will help set the context for clinical genomic sequencing to insure maximum value and quality or our patients and the public."

In defining the need for this document, ACMG said in the Policy Statement, "Major advances in DNA sequencing technology have made it possible to do large-scale sequencing, up to and including whole genome sequencing, in an effort to identify a gene mutation that may provide a diagnosis for a patient with an abnormal phenotype. This strategy offers potential advantages over classic approaches in which genes are analyzed individually, often over a long period of time and at substantial expense. As a result, there is considerable interest in offering genomic sequencing-based tests on a clinical basis. This document outlines points to consider in the clinical application of genomic sequencing to the detection of germ-line mutations. It is expected that this document will require revision as this rapidly changing field evolves."

One of the main conclusions/recommendations of the Policy Statement is that genomic sequencing data must be integrated in the context of the medical and family history of the individual patient to guide medical decision-making. This should be done by a health provider who is familiar with the enormously complex and voluminous data that is obtained from genomic sequencing.

Advertisement